Persistence of resistant variants in hepatitis c virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 5, 2013, Pages 2054-2065

  Wang, Chunfu ^a   Sun, Jin Hua ^a   O'Boyle, Donald R ^a   Nower, Peter ^a   Valera, Lourdes ^a   Roberts, Susan ^a   Fridell, Robert A ^a   Gao, Min ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ASUNAPREVIR; DACLATASVIR; NONSTRUCTURAL PROTEIN 5A; PLACEBO; RIBAVIRIN; VIRUS RNA;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; FOLLOW UP; GENE SEQUENCE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPLICON; VIRUS LOAD; WILD TYPE;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; MALE; MOLECULAR TYPING; PHENOTYPE; RNA, VIRAL; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84876246624     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02494-12     Document Type: Article

References (16)

1. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun J-H, O'Boyle DR, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG. 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical efficacy. Nature 465:96-100.
2. Fridell RA, Qiu D, Wang C, Valera L, Gao M. 2010. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother. 54:3641-3650.
3. Nettles RE, Gao M, Bifano M, Chung E, Persson A, Marbury T, Goldwater R, DeMicco MP, Rodriguez-Torres M, Vutikullird A, Fuentes E, Lawitz E, Lopez-Talavera JC, Grasela DM. 2011. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 54:1956-1965.
4. Fridell RA, Wang C, Sun JH, O'Boyle DR, Nower P, Valera L, Qiu D, Roberts S, Huang X, Kienzle B, Bifano M, Nettles RE, Gao M. 2011. Genotypic and phenotypic analysis of variants resistant to hepatitisCvirus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 54:1924-1935.
5. Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H. 2012. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 55:742-748.
6. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C. 2012. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366:216-224.
7. Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA, Hezode C, Lim JK, Bronowicki J-P, Abrams GA, Brau N, Morris DW, Thuluvath PJ, Reindollar RW, Yin PD, Diva U, Hindes R, McPhee F, Hernandez D, Wind-Rotolo M, Hughes EA, Schnittman S. 2012. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect. Dis. 12:671-677.
8. Lok A, Gardiner D, Lawitz E, Martorell C, Everson G, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C. 2011. Quadruple therapy with BMS-790052, BMS-650032 and Peg-IFN/RBV for 24 weeks results in 100% SVR12 inHCVgenotype 1 null responders. J. Hepatol. 54(Suppl 1):S536. (Abstract.)
9. Wang C, Huang H, Valera L, Sun JH, O'Boyle DR, II, Nower PT, Jia L, Qiu D, Huang X, Altaf A, Gao M, Fridell RA. 2012. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052. Antimicrob. Agents Chemother. 56:1350-1358.
10. Lemm JA, O'Boyle DR, II, Liu M, Nower PT, Colonno R, Deshpande MS, Snyder LB, Martin SW, St Laurent DR, Serrano-Wu MH, Romine JL, Meanwell NA, Gao M. 2010. Identification of NS5A inhibitors. J. Virol. 84:482-491.
11. Sun JH, O'Boyle DR, II, Zhang Y, Wang C, Nower P, Valera L, Roberts S, Nettles RE, Fridell RA, Gao M. 2012. Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS-790052. Hepatology 55:1692-1699.
12. Sulkowski M, Gardiner D, Lawitz E, Hinestrosa F, Nelson D, Thuluvath P, Rodriguez-Torres M, Lok A, Schwartz H, Reddy KR, Eley T, Wind- Rotolo M, Huang Gao S-PM, McPhee F, Hindes R, Symonds B, Pasquinelli C, Grasela DM. 2012. Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), /ribavirin, in treatment-naïve patients with chronic HCV Gt1, 2 or 3. J. Hepatol. 56(Suppl 2):S560. (Abstract.)
13. Simmonds P. 2004. Genetic diversity and evolution of hepatitis C virus - 15 years on. J. Gen. Virol. 85:3173-3188.
14. Guedj J, Rong L, Dahari H, Perelson AS. 2010. A perspective on modelling hepatitis C virus infection. J. Viral Hepat. 17:825-833.
15. Cuevas JM, Gonzalez-Candelas F, Moya A, Sanjuan R. 2009. Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J. Virol. 83:5760-5764.
16. Combet C, Garnier N, Charavay C, Grando D, Crisan D, Lopez J, Dehne-Garcia A, Geourjon C, Bettler E, Hulo C, Mercier PL, Bartenschlager R, Diepolder H, Moradpour D, Pawlotsky J-M, Rice CM, Trepo C, Penin F, Deleage G. 2007. euHCVdb: the European hepatitis C virus database. Nucleic Acids Res. 35:D363-D366. doi:10.1093/nar /gkl970.